/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Inhibikase Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.43 0.0213(2.13%) IKT at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 1.4
Highest Today 1.47
Today’s Open 1.42
Prev. Close 1.41
52 Week High 4.20
52 Week Low 1.33
Day’s Range: Low 1.4 High 1.47
52-Week Range: Low 1.33 High 4.20
1 day return -
1 Week return -5.84
1 month return -10.49
3 month return -14.95
6 month return -27.86
1 year return -47.65
3 year return -59.72
5 year return -97.58
10 year return -

Institutional Holdings

Sands Capital Ventures, LLC 14.69

Soleus Capital Management, L.P. 8.49

Fairmount Funds Management LLC 8.22

Perceptive Advisors LLC 7.29

COMMODORE CAPITAL LP 7.24

ADAR1 Capital Management LLC 6.87

Vanguard Group Inc 4.33

BlackRock Inc 3.66

Blackstone Inc 3.54

Vanguard Total Stock Mkt Idx Inv 2.99

Nantahala Capital Management, LLC 2.94

Geode Capital Management, LLC 1.43

iShares Russell 2000 ETF 1.11

Stonepine Capital Management Llc 0.98

Fidelity Small Cap Index 0.81

iShares Russell 2000 Value ETF 0.64

State Street Corp 0.53

Northern Trust Corp 0.53

Susquehanna International Group, LLP 0.51

Vanguard Institutional Extnd Mkt Idx Tr 0.46

Vanguard Russell 2000 ETF 0.39

State St Russell Sm Cap® Indx SL Cl I 0.28

Fidelity Extended Market Index 0.25

Blair William & Co 0.21

Charles Schwab Investment Management Inc 0.20

Schwab Small Cap Index 0.20

NT R2000 Index Fund - NL 0.20

FMR Inc 0.19

Fidelity Select Biotechnology 0.19

iShares Micro-Cap ETF 0.19

Bank of New York Mellon Corp 0.18

NT R2000 Index Fund - DC - NL - 3 0.16

Barclays PLC 0.15

iShares Russell 2000 Small-Cap Idx Instl 0.14

Russell 2500™ Index Fund F 0.11

Nuveen Small Cap Blend Idx R6 0.11

Russell 2000 Index Non-Lendable Fund E 0.09

Fidelity Series Total Market Index 0.09

iShares Russell 2000 Growth ETF 0.09

EQ/2000 Managed Volatility IB 0.08

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 119.23 M

PB Ratio 2.5285

PE Ratio 0.0

Enterprise Value 96.70 M

Total Assets 98.60 M

Volume 160424

Company Financials

Annual Revenue FY23:0 0.0M, FY22:123440 0.1M, FY21:3100605 3.1M, FY20:698468 0.7M, FY19:1122740 1.1M

Annual Profit FY23:null 0.0M, FY22:123440 0.1M, FY21:3100605 3.1M, FY20:698468 0.7M, FY19:null 0.0M

Annual Net worth FY23:-19129995 -19.1M, FY22:-17905249 -17.9M, FY21:-14805986 -14.8M, FY20:-2877296 -2.9M, FY19:-5747818 -5.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-23688 -0.0M, Q2/2025:-24157 -0.0M, Q1/2025:-12654 -0.0M, Q3/2024:null 0.0M, Q2/2024:-6569 -0.0M

Quarterly Net worth Q3/2025:-11930280 -11.9M, Q2/2025:-9915523 -9.9M, Q1/2025:-13678735 -13.7M, Q3/2024:-5778066 -5.8M, Q2/2024:-4959608 -5.0M

Fund house & investment objective

Company Information Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Organisation Biotechnology

Employees 15

Industry Biotechnology

CEO Mr. Mark T. Iwicki

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow